Following are specific recommended plasma levels and actions for common bleeding problems and clinical situations which occur with Hemophilia B, also known as Factor IX Deficiency: Assess situation ...

Hemophilia B causes a deficiency in factor IX, a protein necessary for blood clotting. Replacement factor IX therapy is the gold standard treatment, but novel and genetic therapies are showing promise ...

Hemophilia is a rare genetic bleeding disorder affecting clotting ability. Here are its symptoms, treatment options, and ...

Hemophilia B, also called factor IX (FIX) deficiency, is an inherited condition that prevents blood from clotting normally. This means that if you experience a cut, scrape, or injury, the bleeding ...

Haemophilia patients are able to live relatively normal lives with constant observation and moving away of activities that ...

Patients with factor IX deficiency may be treated with a factor IX complex to manage an acute hemorrhage. Factor IX complexes contain 1 unit of factor IX per milligram of protein, with variable ...

The Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor ...

The FDA approved UniQure’s Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency).